Skip to content

US · BLLN · MEDICAL - DIAGNOSTICS & RESEARCH

BillionToOne, Inc. (BLLN) intrinsic value and stock valuation

$89.92as of 2026-11-21 · Mkt cap 6.9B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BillionToOne, Inc. DCF and intrinsic value

InvestorsCraft values BLLN with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from BLLN’s statements →

BillionToOne, Inc. Graham Number

Graham Number: $6.19d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Menlo Park, CA 94025 billiontoone.com

How the business is doing

Fiscal 2023–2025, USD

Revenue
$305.1M
20232025
Net income
$7.45M
20232025
Free cash flow
$15.7M
20232025
Total equity
$480.1M
20232025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2023–2025, USD
202520242023
Revenue$305.1M$152.6M$71.7M
Operating income$16M-$-47.15M-$-69.5M
Net income$7.45M-$-41.57M-$-82.68M
EPSd$162.7K-$-929.56K-$-1.85M
Operating cash flow$24.6M-$-41.38M-$-53.67M
Capital expenditure-$-8.88M-$-5.4M-$-6.17M
Free cash flow$15.7M-$-46.78M-$-59.85M
Total assets$632.7M$302.1M$191.7M
Total debt$108.9M$109.4M$146.4M
Net debt-$-387.08M-$-82.1M$49.1M
Total equity$480.1M$167.8M$30.5M
Cash and short-term investments$496M$191.5M$97.3M
Income statement
202520242023
Revenue$305.1M$152.6M$71.7M
Cost of revenue$96.7M$71.7M$54.4M
Gross profit$208.5M$80.9M$17.3M
Research and development expenses$49.4M$36.6M$22.4M
Selling, general and administrative expenses$143.1M$91.5M$64.4M
Other expenses$0.00$0.00$0.00
Operating expenses$192.4M$128.1M$86.8M
Cost and expenses$289.1M$199.7M$141.2M
Interest income$7.75M$5.82M$3.46M
Interest expense$100K$2.39M$3.27M
Depreciation and amortization$11.9M$11.7M$6.46M
Ebitda$19.8M-$-27.47M-$-72.94M
Operating income$16M-$-47.15M-$-69.5M
Total other income/expenses, net-$-8.26M$5.61M-$-13.18M
Income before tax$7.76M-$-41.54M-$-82.67M
Income tax expense$300K$30K$10K
Net income$7.45M-$-41.57M-$-82.68M
Weighted average shares outstanding$45.8M$44.7M$44.7M
Weighted average diluted shares outstanding$45.8M$44.7M$44.7M
Balance sheet
202520242023
Cash and short-term investments$496M$191.5M$97.3M
Net receivables$41.6M$24.7M$9.09M
Inventory$17.6M$8.73M$7.2M
Total current assets$560.6M$227.8M$115.5M
Property, plant and equipment, net$67.1M$68.9M$73.9M
Goodwill and intangible assets$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00
Total non-current assets$72.1M$74.2M$76.2M
Total assets$632.7M$302.1M$191.7M
Accounts payable$7.18M$4.3M$3.21M
Short-term debt$5.6M$6.22M$53.7M
Deferred revenue$2.19M$2.81M$3.02M
Total current liabilities$48M$28.4M$66.8M
Long-term debt$103.3M$103.2M$92.6M
Deferred revenue, non-current$1.29M$0.00$0.00
Total non-current liabilities$104.6M$105.9M$94.4M
Capital lease obligations$46.1M$51.7M$57.6M
Total liabilities$152.6M$134.3M$161.2M
Common stock$0.00$0.00$0.00
Retained earnings-$-274.75M-$-282.2M-$-240.63M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00
Total equity$480.1M$167.8M$30.5M
Total investments$0.00$0.00$0.00
Total debt$108.9M$109.4M$146.4M
Net debt-$-387.08M-$-82.1M$49.1M
Cash flow statement
202520242023
Net income$2.92M-$-41.57M-$-82.68M
Depreciation and amortization$11.9M$11.7M$7M
Stock-based compensation$15.9M$8.36M$4.85M
Change in working capital-$-22.05M-$-16.77M$3.79M
Accounts receivable-$-16.91M-$-15.62M-$-2.59M
Inventory-$-8.81M-$-1.53M-$-1.41M
Accounts payable$1.77M$880K$150K
Net cash provided by operating activities$24.6M-$-41.38M-$-53.67M
Investments in property, plant and equipment-$-8.92M-$-5.4M-$-6.17M
Acquisitions, net$0.00$0.00$0.00
Net cash used for investing activities-$-8.92M-$-5.43M$82.8M
Common stock issued$290.6M$131.1M$440K
Common stock repurchased$0.00-$-550K$0.00
Dividends paid$0.00$0.00$0.00
Net cash used for financing activities$288.8M$141M$13.4M
Net change in cash$304.5M$94.2M$97.3M
Cash at end of period$496M$191.5M$97.3M
Operating cash flow$24.6M-$-41.38M-$-53.67M
Capital expenditure-$-8.88M-$-5.4M-$-6.17M
Free cash flow$15.7M-$-46.78M-$-59.85M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BillionToOne, Inc.

        BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.

        CEO
        Oguzhan Atay
        Employees
        713
        Beta
        0.34

        Explore

        Frequently asked questions

        What is the intrinsic value of BillionToOne, Inc. (BLLN)?

        BillionToOne, Inc. (BLLN) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is BLLN undervalued?

        BLLN trades at a price of $89.92 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.